| | | 占用方与上市公 | 上市公司核算的 | 2023年期初占用 | 2023年 度1-6月 | 2023年 度1-6月 | 2023年 度1-6月 | 2023年6月3 0日 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 会计科目 | 资金余额 | 占用累计发生金 额（不含利息） | 占用资金的利息 （如 有） | 偿还累计发生金 额 | 占用资金余额 | 因 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥3,085,538,744.52, representing a 46.83% increase compared to ¥2,101,428,825.31 in the same period last year[17] - The total operating revenue for the first quarter of 2023 was RMB 3,085,538,744.52, an increase of 46.9% compared to RMB 2,101,428,825.31 in the same period last year[23] - Net profit attributable to shareholders for Q1 2023 was ¥239,309,926.36, up 57.35% from ¥152,091,656.06 year-over-year[32] - The net profit for the first quarter of 2023 was RMB 239,308,006.44, representing a 57.4% increase from RMB 152,091,656.06 in the same quarter of the previous year[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥233,618,771.10, reflecting a 71.90% increase from ¥135,904,532.94 in the previous year[32] Operating Costs and Expenses - The operating cost for Q1 2023 was ¥2,222,844,353.53, which is a 44.80% increase from ¥1,535,066,594.09 year-on-year, primarily due to the increase in operating revenue[17] - The total operating costs for the first quarter of 2023 were RMB 2,727,579,280.84, up 40.8% from RMB 1,936,664,962.32 in the previous year[24] - R&D expenses increased by 42.14% to ¥202,240,389.62 from ¥142,277,701.47 in the previous year, indicating a significant investment in new product development[17] - Research and development expenses for the first quarter of 2023 amounted to RMB 202,240,389.62, which is a 42.2% increase compared to RMB 142,277,701.47 in the previous year[24] Assets and Liabilities - The company's total assets as of the end of Q1 2023 were ¥12,683,652,944.07, up from ¥12,016,599,023.18 at the beginning of the year[9] - The total liabilities as of the end of the first quarter of 2023 were RMB 6,924,825,286.56, an increase from RMB 6,497,373,460.37 at the end of the previous year[23] - The total liabilities increased, with short-term borrowings rising to ¥673,953,477.78 from ¥562,811,090.10, reflecting increased financing needs[9] - The company's cash and cash equivalents decreased, with other current assets dropping to ¥102,317,739.61 from ¥139,621,228.25, indicating tighter liquidity[9] Cash Flow - The net cash flow from operating activities was ¥222,944,074.02, which is a 29.85% increase compared to ¥171,696,287.82 in the same period last year[32] - Operating cash inflow for the current period reached $2,181,544,246.36, a significant increase from $1,512,778,824.01 in the previous period, reflecting a growth of approximately 44.2%[50] - Cash received from sales of goods and services was $1,996,810,525.10, compared to $1,369,763,853.07, reflecting an increase of about 46.0%[50] - Cash outflow from investing activities was $199,419,106.10, compared to $221,739,313.74 in the previous period, showing a decrease of approximately 10.1%[51] - Net cash flow from financing activities decreased by 71.66% to ¥102,872,647.96 from ¥363,036,069.47 in the previous year, primarily due to increased loan repayments[37] Shareholder Equity - The total equity attributable to shareholders of the parent company was RMB 5,751,482,414.06, up from RMB 5,511,878,399.44 in the previous year[23] - Shareholders' equity attributable to the parent company was ¥5,751,482,414.06, up 4.35% from ¥5,511,878,399.44 at the end of the previous year[32] - The weighted average return on equity for Q1 2023 was 4.24%, an increase from 2.96% in the same period last year[32] Other Information - The company reported a net loss from investment of ¥7,432,195.11, a decline of 178.55% compared to a profit of ¥9,461,798.73 in the previous year[17] - The fair value change income was ¥4,192,034.14, a significant recovery from a loss of ¥4,041,823.60 in the same period last year, indicating improved market conditions[17] - The company has not disclosed any new product developments or market expansion strategies in the provided data[26] - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[27]

重要内容提示： 普洛药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 10 日在《证 券时报》和巨潮资讯网（www.cninfo.com.cn）披露公司 2022 年年度报告。为进 一步加强与投资者的深入交流，使投资者更加全面、深入地了解公司情况，公司 将于 2023 年 3 月 28 日（星期二）下午 15：30-17：00 通过易董价值在线平台 （www.ir-online.cn）举行 2022 年年度业绩说明会。 一、说明会类型 证券代码：000739 证券简称：普洛药业 公告编号：2023－24 普洛药业股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （3）投资者可于 2023 年 3 月 28 日前通过小程序进行会前提问，公司将通 过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回答。 本次业绩说明会以网络方式召开，公司将针对 2022 年年度业绩和经营情况 相关事宜与投资者进行互动交流，在信息披露允许的范围内就投资者普遍关注的 问题进行回答。 二、说明会 ...

Compensation and Remuneration - The total pre-tax compensation for the company's directors and senior management amounted to 1,131.48 million CNY[1]. - The board of directors reviewed and approved the remuneration scheme for directors and senior management for the 2022 fiscal year[6]. - The company distributed cash dividends of ¥33,587.92 million (including tax) during the reporting period, with cumulative cash dividends over the last three years reaching ¥81,671.68 million, representing 35.12% of the net profit in the same period[88]. Internal Controls and Audits - The company conducted an internal control audit, identifying key risk areas and providing corrective measures based on audit findings[17]. - The audit report on internal controls received a standard unqualified opinion, indicating no significant deficiencies in non-financial reporting[20]. - There were no significant defects reported in financial or non-financial internal controls during the reporting period[40]. - The company has not identified any risks during the supervisory activities of the supervisory board in the reporting period[8]. Environmental Compliance and Sustainability - The company reported a significant focus on environmental compliance, with no major environmental incidents occurring throughout the year[34]. - The company has implemented automatic, manual, and periodic monitoring for pollution control, ensuring compliance with national pollution monitoring platforms[32]. - The company has committed to continuous improvement in environmental risk management and has established emergency response measures for environmental incidents[34]. - The company has complied with various environmental protection laws and regulations, ensuring adherence to national standards[43]. - The company has maintained a focus on sustainable practices, aligning its operations with environmental protection initiatives[36]. Research and Development - The company has invested significantly in R&D and project construction to enhance its core competitiveness amid a challenging external environment[67]. - R&D expenses for the reporting period amounted to ¥53,291.97 million, reflecting a year-on-year increase of 10%[99]. - The company has established R&D centers in all three major business segments, with a total of 1,026 R&D personnel, including 46 PhDs and 220 Master's degree holders[104]. - The company emphasizes a continuous increase in R&D investment to enhance its research capabilities and innovation[104]. - The company has increased its R&D personnel by 16.72% from 879 in 2021 to 1,026 in 2022, with the proportion of R&D staff rising from 14.33% to 15.11%[203]. Financial Performance - The company's total revenue for 2022 reached ¥10,544,905,377.17, representing a year-on-year increase of 17.92% compared to ¥8,942,618,232.82 in 2021[93]. - Net profit attributable to shareholders for 2022 was ¥989,173,675.64, a 3.52% increase from ¥955,550,170.21 in 2021[139]. - The net cash flow from operating activities reached ¥1,326,107,316.20, a significant increase of 116.77% compared to ¥611,748,728.68 in 2021[139]. - Total assets at the end of 2022 amounted to ¥12,016,599,023.18, reflecting a 32.86% increase from ¥9,044,671,981.35 at the end of 2021[139]. - The company's basic earnings per share for 2022 was ¥0.8425, up 3.91% from ¥0.8108 in 2021[139]. Market and Business Operations - The company primarily engages in the production of pharmaceutical raw materials, CDMO services, and formulations, adhering to environmental protection laws and industry standards[23]. - The company has a global marketing network covering over 70 countries and regions, with domestic market presence in all provinces except Qinghai and Tibet[64]. - The company's CDMO business revenue was composed of 87% from foreign clients and 13% from domestic clients, with a significant growth in domestic revenue in 2022[70]. - The number of ongoing CDMO projects increased by 62% year-on-year to 524, with 298 projects in the R&D stage (up 108%) and 226 in the commercialization stage (up 26%)[70]. - The company has established a management structure that includes three business divisions: API, CDMO, and FDF, aimed at enhancing operational efficiency[176]. Corporate Governance - The company has developed a self-assessment process for corporate governance, enhancing transparency and accountability[42]. - The company has actively engaged with stakeholders, including shareholders and suppliers, to align business practices with their interests[36]. - The company held its 2021 annual general meeting with a participation rate of 58.13% on March 31, 2022, and disclosed the resolutions on April 1, 2022[198]. - The company conducted its first extraordinary general meeting of 2022 with a participation rate of 54.82% on December 27, 2022, with resolutions disclosed on December 28, 2022[198].

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：1 | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000739 证券简称：普洛药业 编号：2 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...